Scott Owen

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Antonio Passaro, Jing Wang, Yan Wang et al. · Annals of Oncology · 2023 · 396 citations · Full text

Medicine, Oncology, Pharmacology +17

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

Luis Paz‐Ares, Óscar Juan, Giannis Mountzios et al. · Journal of Clinical Oncology · 2024 · 115 citations · Full text

Medicine, Oncology, Pharmacology +17

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Hossein Borghaei, Filippo de Marinis, Daphne W. Dumoulin et al. · Annals of Oncology · 2023 · 93 citations · Full text

Medicine, Oncology, Pharmacology +13

Overall Survival with Amivantamab–Lazertinib in <i>EGFR</i> -Mutated Advanced NSCLC

James Chih‐Hsin Yang, Shun Lu, Hidetoshi Hayashi et al. · New England Journal of Medicine · 2025 · 85 citations

Medicine, Oncology, Pharmacology +15

Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution

M. Azoulay, Fabiano Santos, George Shenouda et al. · Journal of Neuro-Oncology · 2017 · 83 citations

Medicine, Neurosurgery, Oncology +15